377 related articles for article (PubMed ID: 33639695)
21. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
[TBL] [Abstract][Full Text] [Related]
23. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
Casadei-Gardini A; Scartozzi M; Tada T; Yoo C; Shimose S; Masi G; Lonardi S; Frassineti LG; Nicola S; Piscaglia F; Kumada T; Kim HD; Koga H; Vivaldi C; Soldà C; Hiraoka A; Bang Y; Atsukawa M; Torimura T; Tsuj K; Itobayashi E; Toyoda H; Fukunishi S; Rimassa L; Rimini M; Cascinu S; Cucchetti A
Liver Int; 2021 Jun; 41(6):1389-1397. PubMed ID: 33547848
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
[TBL] [Abstract][Full Text] [Related]
26. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N
Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191
[TBL] [Abstract][Full Text] [Related]
27. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
28. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Wang Y; Tan K; Hu W; Hou Y; Yang G
Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
[TBL] [Abstract][Full Text] [Related]
29. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
[TBL] [Abstract][Full Text] [Related]
30. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
[TBL] [Abstract][Full Text] [Related]
31. Beyond the border: the use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines: a retrospective analysis.
Jefremow A; Wiesmueller M; Rouse RA; Dietrich P; Kremer AE; Waldner MJ; Neurath MF; Siebler J
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571964
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
34. Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors.
Uchikawa S; Kawaoka T; Ando Y; Yamaoka K; Kosaka Y; Suehiro Y; Fujii Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Chayama K; Aikata H
Oncology; 2020; 98(10):727-733. PubMed ID: 32712613
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Hu L; Zheng Y; Lin J; Shi X; Wang A
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102061. PubMed ID: 36473632
[TBL] [Abstract][Full Text] [Related]
36. Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma.
Noda S; Iida H; Fujimoto T; Wakasugi Y; Yabuta N; Sudou M; Hira D; Tani M; Andoh A; Morita SY; Terada T
Cancer Chemother Pharmacol; 2021 Aug; 88(2):281-288. PubMed ID: 33928425
[TBL] [Abstract][Full Text] [Related]
37. Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Koizumi A; Komatsu S; Omiya S; Yano Y; Fujishima Y; Ishida J; Kido M; Gon H; Fukushima K; Urade T; So S; Yoshida T; Arai K; Fujinaka R; Shimura Y; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2024 May; 44(5):2055-2061. PubMed ID: 38677746
[TBL] [Abstract][Full Text] [Related]
38. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.
Rapposelli IG; Shimose S; Kumada T; Okamura S; Hiraoka A; Di Costanzo GG; Marra F; Tamburini E; Forgione A; Foschi FG; Silletta M; Lonardi S; Masi G; Scartozzi M; Nakano M; Shibata H; Kawata K; Pellino A; Vivaldi C; Lai E; Takata A; Tajiri K; Toyoda H; Tortora R; Campani C; Viola MG; Piscaglia F; Conti F; Fulgenzi CAM; Frassineti GL; Rizzato MD; Salani F; Astara G; Torimura T; Atsukawa M; Tada T; Burgio V; Rimini M; Cascinu S; Casadei-Gardini A
ESMO Open; 2021 Aug; 6(4):100190. PubMed ID: 34144271
[TBL] [Abstract][Full Text] [Related]
39. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
[TBL] [Abstract][Full Text] [Related]
40. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma.
Briggs A; Daniele B; Dick K; Evans TRJ; Galle PR; Hubner RA; Lopez C; Siebert U; Tremblay G
Br J Cancer; 2020 Jun; 122(12):1754-1759. PubMed ID: 32265508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
